AbbVieABBV
ABBV
About: AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Employees: 50,000
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 11 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
230% more first-time investments, than exits
New positions opened: 241 | Existing positions closed: 73
32% more capital invested
Capital invested by funds: $234B [Q2] → $310B (+$75.7B) [Q3]
22% more call options, than puts
Call options by funds: $3.71B | Put options by funds: $3.03B
18% more funds holding in top 10
Funds holding in top 10: 174 [Q2] → 206 (+32) [Q3]
4% more funds holding
Funds holding: 3,301 [Q2] → 3,427 (+126) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 1,381 | Existing positions reduced: 1,378
3.38% less ownership
Funds ownership: 76.83% [Q2] → 73.44% (-3.38%) [Q3]
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$191
12%
upside
Avg. target
$209
23%
upside
High target
$224
32%
upside
11 analyst ratings
9 positive
82%
2 neutral
18%
0 negative
0%
Truist Securities Srikripa Devarakonda 30% 1-year accuracy 10 / 33 met price target | 24%upside $211 | Buy Maintained | 8 Jan 2025 |
Piper Sandler Christopher Raymond 13% 1-year accuracy 4 / 30 met price target | 29%upside $220 | Overweight Maintained | 17 Dec 2024 |
B of A Securities Tim Anderson 67% 1-year accuracy 4 / 6 met price target | 12%upside $191 | Neutral Reinstated | 10 Dec 2024 |
Leerink Partners David Risinger 20% 1-year accuracy 2 / 10 met price target | 21%upside $206 | Outperform Upgraded | 22 Nov 2024 |
Wolfe Research Alexandria Hammond 33% 1-year accuracy 3 / 9 met price target | 20%upside $205 | Outperform Initiated | 15 Nov 2024 |
Financial journalist opinion
Based on 56 articles about ABBV published over the past 30 days
Positive
InvestorPlace
11 hours ago
3 More Cyclical Stocks to Buy for 2025
In last week's Sunday Digest, I (Tom Yeung) wrote how cyclical companies are often incredible investments. Firms like copper miner Freeport–McMoRan Inc. ( FCX ) usually trade in a predetermined range (much like high and low tides at a beach), and so investors simply need to learn that range and the pattern the stock follows, and then buy low and sell high.
Positive
Seeking Alpha
16 hours ago
AbbVie: Q4 2024 Earnings Preview And Update On Emraclidine
AbbVie is expected to beat Q4 2024 revenue and EPS estimates, with strong performance from Skyrizi, Rinvoq, and neuroscience products offsetting Humira's decline. Management expects a return to "robust" mid-single-digit revenue growth in 2025, which suggests full-year 2025 guidance will be largely in line with the analyst consensus. AbbVie is not giving up on emraclidine based on trial conduct and drug exposure observations in the failed phase trial in schizophrenia patients in late 2024.
Positive
Seeking Alpha
1 day ago
5 Best CEFs This Month For Nearly 10% Yield (January 2025)
For income investors, closed-end funds, or CEFs, remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. CEFs are generally characterized by higher volatility and deeper draw-downs than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs with solid track records that pay high distributions and offer “excess” discounts. We try to separate the wheat from the chaff using our filtering process to select just five CEFs every month from around 500 closed-end funds.
Negative
Zacks Investment Research
2 days ago
Earnings Preview: AbbVie (ABBV) Q4 Earnings Expected to Decline
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
Zacks Investment Research
2 days ago
AbbVie Inks a Deal With Neomorph for Molecular Glue Degraders
Per the terms of the deal, AbbVie will use Neomorph's proprietary platform to develop novel drugs targeting oncology and immunology indications.
Positive
Seeking Alpha
2 days ago
My Near-Perfect Retirement Dividend Portfolio
Low-volatility, dividend growth stocks offer long-term outperformance and a favorable risk profile, despite lower yields during bull markets. Dividend growth portfolios can significantly increase yields over time, making them a strong choice for retirement-focused investors. The 4% rule remains a valid strategy for retirement, but adjustments may be needed due to increasing life expectancies.
Positive
The Motley Fool
2 days ago
Is AbbVie Stock a Buy?
Pharmaceutical powerhouse AbbVie (ABBV 0.87%) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while raising its dividend by an average of 14% annually.
Neutral
Seeking Alpha
2 days ago
What Can The Dividend Kings Deliver In 2025?
The Dividend Kings underperformed the broad U.S. equity market in 2024, achieving a 5.53% total return compared to the S&P 500's 24.89%. 2024 returns for the Dividend Kings were primarily driven by earnings growth and dividends, with the change in P/E ratio being a detractor. I breakdown the components of total return for each Dividend King by sector to gain insights into current valuation.
Neutral
PRNewsWire
3 days ago
AbbVie Completes Acquisition of Nimble Therapeutics
Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie's pipeline and R&D capabilities NORTH CHICAGO, Ill. , Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Nimble Therapeutics.
Neutral
PRNewsWire
3 days ago
AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology
Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is eligible to receive future option fees and milestones of up to $1.64B NORTH CHICAGO, Ill. and SAN DIEGO , Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology and immunology.
Charts implemented using Lightweight Charts™